ArticleEuropean surgery : ACA : Acta chirurgica Austriaca2018

• Pancho trial (p53-adapted neoadjuvant chemotherapy for resectable esophageal cancer) completed-mutation rate of the marker higher than expected.

Sonja Kappel-Latif et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.